Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-03-20
2010-11-30
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S369000, C514S376000, C514S340000, C546S269700, C546S271400, C548S183000, C548S227000
Reexamination Certificate
active
07842706
ABSTRACT:
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
REFERENCES:
patent: 3454635 (1969-07-01), Weber et al.
patent: 4863922 (1989-09-01), Baldwin et al.
patent: 4895862 (1990-01-01), Alessi et al.
patent: 5068342 (1991-11-01), Zask et al.
patent: 5356913 (1994-10-01), Colca
patent: 5798375 (1998-08-01), Tsujita et al.
patent: 5859037 (1999-01-01), Whitcomb
patent: 5965584 (1999-10-01), Ikeda et al.
patent: 5972973 (1999-10-01), Whitcomb
patent: 6011049 (2000-01-01), Whitcomb
patent: 6329404 (2001-12-01), Ikeda et al.
patent: 6911459 (2005-06-01), Ikeda et al.
patent: 0 008 203 (1980-02-01), None
patent: 0 193 256 (1986-09-01), None
patent: 0 306 228 (1989-03-01), None
patent: 0 482 498 (1992-04-01), None
patent: 0 710 659 (1996-05-01), None
patent: 0 749 751 (1996-12-01), None
patent: 1 174 135 (2002-01-01), None
patent: 861 666 (2003-12-01), None
patent: 57-28073 (1982-02-01), None
patent: 64-71813 (1989-03-01), None
patent: 4-066579 (1992-03-01), None
patent: 4-069383 (1992-03-01), None
patent: 4-282324 (1992-10-01), None
patent: 5-202042 (1993-08-01), None
patent: 7-316144 (1995-12-01), None
patent: WO 88/06887 (1988-09-01), None
patent: WO 92/03148 (1992-03-01), None
patent: WO 93/03724 (1993-03-01), None
Whitcomb et al., “Oncologic, Endocrine & Metabolic,” Thiazolidinediones, Section Review, Ashley Publications Ltd., 1995, pp. 1299-1309.
Kazuya et al., A Pilot Clinical Trial of a New Oral Hypoglycemic Agent, CS-045, in Patients with Non-Insulin Dependent Diabetes Mellitus, Diabetes Research and Clinical Practice, Elsevier, vol. 11, 1991, pp. 147-154.
Cantello et al., “[[α-(Heterocyclylamino)Alkoxy]Benzyl]-2-4-Thiazolidinediones As Potent Antihyperglycemic Agents,” Journal of Medicinal Chemistry, American Chemical Society, vol. 37, No. 23, 1994, pp. 3977-3985.
Lebovitz, “Oral Antidiabetic Agents,” Drugs, vol. 44, Adis International Limited, pp. 21-28, 1992.
Ishida et al., “Oral Hypoglycemic Agents—New Oral Drugs and New Strategy of Treatment,” English Translation of “Clinic All-Round”, vol. 43, pp., 1994, 2615-2621.
M. Tominaga et al. “Thiazolidinediones (AD-4833 and CS-045) Improve Hepatic Insulin Resistance in Streptozotocin-Induced Diabetic Rats,” Endocrine Journal, 1993, vol. 40, No. 3, pp. 345-349.
C. Hofmann et al., “Glucose Transport Deficiency in Diabetic Animals is Corrected by Treatment with the Oral Antihyperglycemic Agent Pioglitazone,” Endocrinology, 1991, vol. 129, No. 4, pp. 1915-1925.
J. Karam, “Type II Diabetes and Syndrome X,” Endocrinology and Metabolism Clinics of North America, 1992, vol. 21, No. 2, pp. 329-350.
S. Suter et al., “Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects,” Diabetes Care, 1992, vol. 15, No. 2, pp. 193-203.
T. Toyoda, Iyaku Journal, 1994, vol. 30, No. 4, pp. 1130-1134.
Y. Sugiyama et al., “Effects of Pioglitazone on Glucose and Lipid Metabolism in Wistar Fatty Rats,” Arzneim.-Forsch/Drug Res., 1990, vol. 40, No. 1, pp. 263-267.
Ishida et al., “Oral Hypoglycemic Agents—New Oral Drugs and New Strategy of Treatment,” Clinic Allround, 1994, vol. 43, pp. 2615-2621, (and English translation).
Russian Document and its English Translation—Edited by Professor N. T. Starkova, “Clinical Endocrinology,” A textbook for Physicians, pp. 236-239, 1991.
Therapeutic Research, 1993, 14 (No. 10), 4122 to 4126 (and English translation).
Clinic and Medicine, 1993, 9 (Suppl. 3), 19 to 37.
Clinic and Medicine, 1993, 9 (Suppl. 3), 39 to 60.
Recent Medicine, 1982, 33 197.
Sugiyama et al., “Effects of Pioglitazone on Hepatic and Peripheral Insulin Resistance in Wistar Fatty Rats,” Arzneim.-Forsch., 1990, vol. 40, pp. 436-440.
Ikeda et al., “Effects of Pioglitazone on Glucose and Lipid Metabolism in Normal and Insulin Resistant Animals,” Arzneim.-Forsch., 1990, vol. 40, pp. 156-162.
Hofmann et al., “New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers,” Diabetes Care, 1992, vol. 15, pp. 1075-1078.
Hofmann et al., “Treatment of Insulin-Resistant Mice with the Oral Antidiabetic Agent Pioglitazone: Evaluation of GLUT2 and Phosphoenolpyruvate Carboxykinase Expression,” Endocrinology, 1992, vol. 130, pp. 735-740.
Iwanishi et al., “Effect of Pioglitazone on Insulin Receptors of Skeletal Muscles from High Fat-Fed Rats,” Metabolism, 1993, vol. 42, pp. 1017-1021.
Iwanishi et al., “New Oral Agent to Increase Insulin Sensitivity by Activating Kinase Activity of Insulin Receptors,” 1990, Diabetes, vol. 39, abstract 474.
Kobayashi et al., “Pioglitazone Increases Insulin Sensitivity by Activating Insulin Receptor Kinase,” Diabetes, 1992, vol. 41, pp. 476-483.
Hofmann et al., “Insulin Sensitization in Diabetic Rat Liver by an Antihyperglycemic Agent,” Metabolism, 1995, vol. 44, pp. 384-389.
de Souza et al., “Insulin Secretory Defect in Zucker fa/fa Rats is Improved by Ameliorating Insulin Resistance,” Diabetes, 1995, vol. 44, pp. 984-991.
Hofmann et al., “Glucose Transport Deficiency in Diabetic Animals is Corrected by Treatment with the Oral Antihyperglycemic Agent Pioglitazone,” Endocrinology, 1991, vol. 129, pp. 1915-1925.
Colca et al., “Antihyperglycaemic Thiazolidinediones: Ciglitazone and its Analogues,” New Antidiabetic Drugs, 1990, pp. 255-261.
Tominaga et al., “Thiazolidinediones (AD-4833 and CS-045) Improve Hepatic Insulin Resistance in Streptozotocin-Induced Diabetic Rats,” Endocrine Journal, 1993, vol. 40, pp. 343-349.
Weinstock et al., “Pioglitazone: In Vitro Effects on Rat Hepatoma Cells and in vivo Liver Hypertrophy in KKAγMice,” Pharmacology, 1997, vol. 54, pp. 169-178.
El-Kebbi et al., “Regulation of Glucose Transport by Pioglitazone in BC3H-1 Myocytes,” Clinical Research, 1991, vol. 39, p. 837A.
Kemnitz et al., “Pioglitazone Increases Insulin Sensitivity, Reduces Blood Glucose, Insulin, and Lipid Levels, and Lowers Blood Pressure in Obese, Insulin-Resistant Rhesus Monkeys,” Diabetes, 1994, vol. 43, pp. 204-211.
Meehan et al., “Pioglitazone Reduces Blood Pressure and Improves Insulin Sensitivity in Fructose-Fed Rats,” Clinical Research, 1993, vol. 41, p. 21A.
Colca et al., “Pioglitazone Hydrochloride Inhibits Cholesterol Absorption and Lowers Plasma Cholesterol Concentrations in Cholesterol-Fed Rats,” 1991, Diabetes, vol. 40, pp. 1669-1674.
Sohda et al., “Studies on Antidabetic Agents, 11. Novel Thiazolidinedione Derivatives as Potent Hypoglycemic and Hypolipidemic Agents,” Journal of Medicinal Chemistry, 1992, vol. 35, pp. 2617-2626.
Sugiyama et al., “Pathogenesis Hyperglycemia in Genetically Obese-Hyperglycemic Rats, Wistar Fatty: Presence of Hepatic Insulin Resistance,” Endocrinologia Japonica, 1989, vol. 36, pp. 65-73.
Suter et al., “Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects,” Diabetes Care, 1992, vol. 15, pp. 193-203.
Iwamoto et al., Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM, Diabetes Care, 1991, vol. 14, pp. 1083-1086.
Norris et al., Comparison of Troglitazone (C1991) Dosing Regimens and Placebo in the Treatment of Patients with NIDDM, Diabetes, 1993, vol. 42, Supp. 1, Abstract 188.
Fukuda et al., “Results of a Pilot Study in which Troglitazone and Insulin were Jointly Administered to NIDDM Patients,” Journal of Clinical Therapeutics & Medicines, 1995, vol. 11, pp. 2055-2062 (with translation, based on abstract published at 15th Diabetes Fed. Cong., Nov. 6-11, 1994, Kobe).
K
Ikeda Hitoshi
Odaka Hiroyuki
Sohda Takashi
Davis Zinna N
Foley & Lardner LLP
Takeda Pharmaceutical Company Limited
LandOfFree
Pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4155697